CD19 drugs for Follicular Lymphoma

2 tracked CD19 drugs in the Follicular Lymphoma race. The class explanation lives on the CD19 page; the full indication pipeline across every mechanism is on the Follicular Lymphoma page.

1 approved / phase 41 Phase 1/2

Head-to-head evidence: Tafasitamab vs Zugocabtagene geleucel

The roster

← all CD19 drugs